Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

Neurogastroenterology and motility - 1 Apr 2012

Wong B S, Camilleri M, Eckert D, Carlson P, Ryks M, Burton D, Zinsmeister A R

Abstract excerpt

BACKGROUND: Genetic variation in endocannabinoid metabolism is associated with colonic transit in irritable bowel syndrome (IBS) with diarrhea (IBS-D). The nonselective cannabinoid (CB) receptor agonist, dronabinol (DRO), reduced fasting colonic motility in nonconstipated IBS. FAAH and CNR1 variants influenced DRO's effects on colonic motility. Our aims were: (i) to compare dose-related effects of DRO to placebo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Analgesics, Non-Narcotic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Dose-Response Relationship, Drug

Share to Double-Blind Method

Share to Genomics

Share to Irritable Bowel Syndrome

Share to Receptor, Cannabinoid, CB1

Source

Open in PubMed Open full text

Identifiers

PMID: 22288893
DOI: 10.1111/j.1365-2982.2011.01874.x
PMCID: PMC3775711

Genes

CNR1
FAAH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.PMID 22288893Read ↗

Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.Semantic proximity Read ↗

Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation.Semantic proximity Read ↗

Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits.Semantic proximity Read ↗

Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.Semantic proximity Read ↗

Cannabinoids and the gut: new developments and emerging concepts.Semantic proximity Read ↗

Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.Semantic proximity Read ↗

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.Semantic proximity Read ↗

Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?Semantic proximity Read ↗

Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.Semantic proximity Read ↗

Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.Semantic proximity Read ↗

Pharmacogenetics of low dose clonidine in irritable bowel syndrome.Semantic proximity Read ↗

Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.